

II

wherein W is optionally substituted aryl; optionally substituted C_5-C_7 cycloalkyl; -CHR^1R^2 where R^1 and R^2 are independently selected from hydrogen, optionally substituted C_1-C_6 alkyl, optionally substituted C_3-C_7 cycloalkyl and optionally substituted aryl; OR' where R' is optionally substituted aryl; optionally substituted C_3-C_7 cycloalkyl; or optionally substituted C_1-C_6 alkyl; provided that R^1 and R^2 are not both hydrogen;

Z is imino, C_1-C_2 alkylene, -CH_2NH- or -CH_2CH_2NH-;

X is O or S; and

Y is optionally substituted C_2-C_3 alkylene; provided that W is not OR' when Z is imino or - CH_2NH-;

or a pharmaceutically acceptable salt or ester thereof.

46. A method according to claim 45 wherein the disease of the central nervous system is selected from dementia, mood disturbances, degenerative conditions such as stroke or aging, ischaemia, CNS trauma, and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

47. A method of the treatment or prevention of glaucoma comprising administering an effective amount of a compound of formula II



II

wherein W is optionally substituted aryl; optionally substituted C_5-C_7 cycloalkyl; -CHR^1R^2 where R^1 and R^2 are independently selected from hydrogen, optionally substituted C_1-C_6 alkyl, optionally substituted C_3-C_7 cycloalkyl and optionally substituted aryl; OR' where R' is optionally substituted aryl; optionally substituted C_3-C_7 cycloalkyl; or optionally substituted C_1- C_6 alkyl; provided that R^1 and R^2 are not both hydrogen;

Z is imino, C_1-C_2 alkylene, -CH_2NH- or -CH_2CH_2NH-;

X is O or S; and

Y is optionally substituted C_2-C_3 alkylene; provided that W is not OR' when Z is imino or -CH_2NH-; and

with the further provisos that

a) when Y is CH_2CH_2, X is O and Z is imino then

(i) if W is CHR^1R^2 and R^1 is H then R^2 is not selected from phenyl; phenyl substituted with methoxy, Br, Cl, F or trifluoromethyl; 3-nitrophenyl; 3- or 4-

methylphenyl; 2- or 4-bromomethyl phenyl; 2- or 4-chloromethylphenyl; or 2,3- or 2,6-dimethylphenyl; and

(ii) if W is CHR^1R^2 and R^1 is CH_3 or cyclopropyl then R^2 is not phenyl or phenyl substituted with alkyl, halomethyl, fluoro or trifluoromethyl; and

b) when Y is $(CH_2)_{2-4}$, X is O or S, Z is imino and W is CHR^1R^2, then

(i) if R^1 is CF_3, CF_2CF_3 or $CF_2CF_2CF_3$ then R^2 is not alkyl, optionally substituted cycloalkyl or optionally substituted aryl, and

(ii) if R^1 is optionally substituted cyclopropyl, R^2 is not H, alkyl or optionally substituted cyclopropyl;

or a pharmaceutically acceptable ester or salt thereof, to a subject in need thereof.

48. A method for the treatment of diseases of the central nervous system, cardiovascular system, or the kidney, or diseases associated with abnormal adrenal gland secretions, or in the

treatment or prevention of hyperglycaemia, glaucoma, peptic ulcer or to produce analgesia which comprises administering an effective amount of a compound of formula II



II

wherein W is optionally substituted aryl; optionally substituted C_5-C_7 cycloalkyl; -CHR^1R^2 where R^1 and R^2 are independently selected from hydrogen, optionally substituted C_1-C_6 alkyl, optionally substituted C_3-C_7 cycloalkyl and optionally substituted aryl; OR' where R' is optionally substituted aryl; optionally substituted C_3-C_7 cycloalkyl; or optionally substituted C_1-C_6 alkyl; provided that R^1 and R^2 are not both hydrogen;

Z is imino, C_1-C_2 alkylene, -CH_2NH- or -CH_2CH_2NH-;

X is O or S; and

Y is optionally substituted C_2-C_3 alkylene; provided that W is not OR' when Z is imino or -CH_2NH-; and

with the further provisos that

a) when Y is CH_2CH_2, X is O and Z is imino then

(i) W is not unsubstituted or 2-mono-, 2,2-di, 2,5-di, 2,6-di or 2,4,6-tri C_{1-3} alkyl substituted cyclohexyl or 2-mono- or 2,5,-di C_{1-3} alkyl substituted cyclopentyl or 2-C_{1-3} alkyl substituted cycloheptyl; and

(ii) if W is CHR^1R^2 and R^1 is H then R^2 is not selected from phenyl; phenyl substituted with methoxy, Br. Cl, F or trifluoromethyl; 3-nitrophenyl; 3- or 4-methylphenyl; 2- or 4-bromomethylphenyl; 2- or 4-chloromethylphenyl; or 2,3- or 2,6 dimethylphenyl; and

(iii) if W is CHR^1R^2 and R^1 is CH_3 or cyclopropyl then R^1 is not phenyl or phenyl substituted with alkyl, halomethyl, fluoro or trifluoromethyl; and

b) when Y is $(CH_2)_{2-4}$, X is O or S, Z is imino and W is CHR^1R^2, then

(i) if R^1 is CF_3, CF_2CF_3 or $CF_2CF_2CF_3$ then R^2 is not alkyl, optionally substituted cycloalkyl or optionally substituted aryl, and

(ii) if R^1 is optionally substituted cyclopropyl, R^2 is not H, alkyl or optionally substituted cyclopropyl;

or a pharmaceutically acceptable ester or salt thereof, to a subject in need thereof.